SCHEMBL504863

SCHEMBL504863

N#CN/C(=N\c1ccncc1)NCCCCCCCOc1ccc(Cl)cc1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 4/20 0.61
CYP3A4 P08684 1/20 0.61
CYP2D6 P10635 1/20 0.61
CYP2C9 P11712 1/20 0.61
CYP2C19 P33261 1/20 0.61
IKBKB O14920 1/20 0.59
ALDH3A1 P30838 1/20 0.39
KMT2A Q03164 1/20 0.38
HRH4 Q9H3N8 2/20 0.38
ALDH1A1 P00352 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
LARS1 Q9P2J5 1/20 0.37
HRH3 Q9Y5N1 2/20 0.36
HRH2 P25021 1/20 0.36
HRH1 P35367 1/20 0.36
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL504864 1.00 NAMPT (0.61) NAMPTCYP3A4CYP2D6CYP2C9CYP2C19
Chs-828 SCHEMBL504892 1.00 NAMPT (0.61) NAMPTCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL504126 1.00 NAMPT (0.61) NAMPTCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL505053 1.00 NAMPT (0.61) NAMPTCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL504982 1.00 NAMPT (0.61) NAMPTCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL504997 1.00 NAMPT (0.61) NAMPTCYP3A4CYP2D6CYP2C9CYP2C19
Chs-828 SCHEMBL504151 1.00 NAMPT (0.61) NAMPTCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL504983 1.00 NAMPT (0.61) NAMPTCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL505054 1.00 NAMPT (0.61) NAMPTCYP3A4CYP2D6CYP2C9CYP2C19
Chs-828 SCHEMBL504150 1.00 NAMPT (0.61) NAMPTCYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120029036-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDYL CYANOGUANIDINE, PROCESS FOR PREPARING THE SAME AND USE THEREOF TIANJIN MICHELE SCI-TECH DEVELOPMENT CO., LTD. (CN) 2012-02-02 US claimed
EP-2394649-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDYL CYANOGUANIDINES, PREPARATION METHODS AND USES THEREOF Tianjin Hemay Bio-Tech Co., Ltd. (CN) 2011-12-14 EP claimed
US-20120029036-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDYL CYANOGUANIDINE, PROCESS FOR PREPARING THE SAME AND USE THEREOF TIANJIN MICHELE SCI-TECH DEVELOPMENT CO., LTD. (CN) 2012-02-02 US disclosed
EP-2394649-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDYL CYANOGUANIDINES, PREPARATION METHODS AND USES THEREOF Tianjin Hemay Bio-Tech Co., Ltd. (CN) 2011-12-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120029036-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDYL CYANOGUANIDINE, PROCESS FOR PREPARING THE SAME AND USE THEREOF PLPBP, PYGL, QDPR NAMPT 511/4885CYP3A4 117/4885CYP2D6 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.